Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Non-Current Assets (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Non-Current Assets for 6 consecutive years, with $35.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 4.9% year-over-year to $35.0 million, compared with a TTM value of $142.3 million through Sep 2025, down 3.12%, and an annual FY2024 reading of $36.2 million, up 5.22% over the prior year.
  • Non-Current Assets was $35.0 million for Q3 2025 at Ovid Therapeutics, down from $35.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $38.4 million in Q1 2024 and bottomed at $793980.0 in Q1 2021.
  • Average Non-Current Assets over 5 years is $25.3 million, with a median of $33.3 million recorded in 2023.
  • The sharpest move saw Non-Current Assets dropped 19.45% in 2021, then soared 2546.02% in 2022.
  • Year by year, Non-Current Assets stood at $4.1 million in 2021, then soared by 487.49% to $23.9 million in 2022, then surged by 44.14% to $34.4 million in 2023, then grew by 5.22% to $36.2 million in 2024, then decreased by 3.32% to $35.0 million in 2025.
  • Business Quant data shows Non-Current Assets for OVID at $35.0 million in Q3 2025, $35.3 million in Q2 2025, and $35.7 million in Q1 2025.